

Novita Healthcare AGM – 30 October 2017

CHAIRMAN'S ADDRESS

Good morning. I appreciate the opportunity to address our shareholders and to welcome you to the 2017 Annual General Meeting of Novita Healthcare ("AGM").

First, thank you for your attendance today. It is pleasing to see many long-standing shareholders in the audience and to welcome a number of new supporters to our meeting today.

On behalf of the Company, I am pleased to report a year of substantial progress in Novita's transformation. We are now solely focused on the exciting med-tech sector of the healthcare market. Within the last year we have acquired Newly and made substantial progress towards commercialising TALI, which we acquired in the previous financial year.

As many of you will know, I took the decision in August to step down from my role as Executive Chairman and Director of the Company after seven years on the Board.

Our new Chief Executive Officer, Mr. Glenn Smith has assumed the role at an exciting time for Novita and it is appropriate that the Board is also refreshed. As has been announced to the ASX, we are delighted to welcome Mr. Bruce Higgins to the Board as a Director and, from today, as Chairman of Novita Healthcare.

Individually, both Mr. Higgins and Mr. Smith have strong credentials in their respective areas of expertise and, importantly, in the leadership of rapidly growing businesses. I am also convinced that that Bruce and Glenn will work closely together to realise the potential within the Novita group and capitalise on growth opportunities going forward and deliver value to all of the Company's stakeholders.

As I will not be seeking re-election at today's AGM. I would like to take this opportunity to express my pleasure in serving on the Board over the past seven years, and in contributing to the Company's transformation to Novita Healthcare.

In concluding my address, I would like to thank my fellow Directors for their support during my tenure. I would also like to express my appreciation for the ongoing support of all investors, patients, clinicians, carers, staff and stakeholders as Novita continues to forge its new path of growth in the med-tech sector.